Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, ...

NORTH CHICAGO, Ill., Sept. 12, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced top-line results from the Phase 3 SEQUENCE clinical trial evaluating risankizumab (SKYRIZI ®, 600 mg intravenous ...

Celltrion has obtained the Food and Drug Administration’s clearance for a new presentation of Steqeyma (ustekinumab-stba), a biosimilar to Stelara (ustekinumab), in a 45mg/0.5ml solution in a ...

Funding a head-to-head study against a rival is risky. When that rival’s initials are “J” and “J,” it’s an even riskier bet. However, it’s just the sort of endeavor that appears to have paid off for ...

Celltrion is introducing Steqeymaq (ustekinumab-stba), which is a biosimilar to Johnson & Johnson's Stelara (ustekinumab). Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic ...

New data show proportions of patients treated with TREMFYA who achieved clinical-biomarker response ranged from 47.5-66.7 percent across dose groups in the Phase 2 GALAXI 1 study Other data presented ...

Topline results were announced from a head-to-head study comparing risankizumab (Skyrizi ®) to ustekinumab (Stelara ®) in patients with moderately to severely active Crohn disease who have failed at ...

The MarketWatch News Department was not involved in the creation of this content. -- Steqeyma(R) (CT-P43), is now approved in Canada for adult patients with plaque psoriasis as well as adults with ...

* The first primary endpoint was clinical remission (per CDAI) at week 24, and the second primary endpoint was endoscopic remission (per SES-CD) at week 48. Non-inferiority was met for the first ...